参考文献/References:
[1] Pastore AL, Mariani S, Barrese F, et al. Transurethral resection of prostate and the role of pharmacological treatment with dutasteride in decreasing surgical blood loss[J]. J Endourol, 2013, 27(1) : 68-70.
[2] Chapple CR. Pharmacological therapy of benigh prostatic hyperplasia/lower urinary tract symptoms:An overview for the practicing clinician[J]. BJU Int, 2004, 94(5): 738-744.
[3] Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia[J] .J Urol, 2004, 172(4 Pt 1): 1399-1403.
[4] Aweimer A, Stachon T, Tannapfel A, et al. Regulation of soluble VEGFR-2 secrted by microvascular endothelial cells derived from human BPH[J]. Prostate Cancer Prstatic Dis, 2012, 15 (2): 157-614
[5] 宋焕涛, 彭晓霞, 杨称称等. 非那雄胺对TURP 术中出血的影响及机制的Meta 分析 [J]. 山东医药, 2012, 51(52): 22-23.
[6] Arena F. Specific antigen prostatic changes during treatment wtih finasteride or dutasteride for benign prostatic hyperplasia[J] .Minerva Urol Nefrol, 2013, 65(3): 211-216.
[7] Fenter TC, Davis EA, Shah MB, et al. Dutasteride vs finasteride:assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged> or =65 years. [J] AM J Manag care, 2008, 14(5 Suppl 2): S154-S159
[8] 张元芳, 叶烈夫等. 不同前列腺组织中睾酮及双氢睾酮含量测定的研究[J]. 中华外科杂志, 2000, 7(38): 545-547.
[9] Partin AW, Rodriguez R. The molecular biology,Endocrinology,and Physiology of the Prostate and Seminal Vesicles[A]. In: Walsh CP,ed.Campbell's Urology[M]. 8 th， ed. Philadelphia: Elsevier science,2002: 1235-1296.
[10] Cindolo L, Alvarez-Maestro M, Castellucci R, et al.Efficacy and safety of dutasteride for the treatment of symptomatic benignr opstatic hyperplasia(BPH): a systematic review and meta-analysis [J].World J Urol, 2015, 33(3): 441-442
[11] Kido LA , Hetzl AC, Andido EM, et al. Antiangiogenic and finasteride therapies: responses of the prostate microenvironmnet in elderly mice[J]. Life Sci, 2014, 106(1-2): 58-70.
[12] 江东, 郭振宇、麦蕾等. 围手术期应用度他雄胺对经尿道前列腺等离子切除术出血量的影响[J/CD]. 中华腔镜泌尿外科杂志: 电子版, 2014, 8(5): 46-49.
[13] 陈向新, 尹杰, 麦能斌, 等. 非那雄胺在经尿道前列腺电切术后镜下血尿阴转中的作用[J]. 新医学, 2003, 34(11): 679-680.
[14] Roehrborn CG, Marks LS, Fenter T, et al. Eficacy and safety of dutasteride in the four-year treatment of men with benign prtoastic hyperplasia[J]. Urology, 2004, 63( 4 ): 709-715.
相似文献/References:
[1]江东 延敏博 麦蕾 郭振宇 郭惠学 郭德荣.度他雄胺联合坦索罗辛治疗高危前列腺增生的临床观察[J].中华腔镜泌尿外科杂志(电子版),2016,10(01):30.[doi:10.3877/cma.j.issn.1674-3253.2016.01.008
]
Jiang Dong,Yan Minbo,Mai Lei,et al.Clinical observation of high-risk benign prostatic hyperplasia treated with dutasteride and tamsulosin[J].,2016,10(03):30.[doi:10.3877/cma.j.issn.1674-3253.2016.01.008
]
[2]江东 郭振宇 麦蕾 冯旭升 郭德荣.围手术期应用度他雄胺对经尿道前列腺等离子切除术出血量的影响[J].中华腔镜泌尿外科杂志(电子版),2014,(05):366.[doi:10.3877/cma.j.issn.1674-3253.2014.05.013
]
Jiang Dong,Guo Zhenyu,Mai Lei,et al.The effect on bleeding volume of transurethral plasmakinetic prostatectomy by perioperative use of dutasteride[J].,2014,(03):366.[doi:10.3877/cma.j.issn.1674-3253.2014.05.013
]